This year, Italian company Procos marks two important milestones: 80 years since its establishment and 20 years since its acquisition by CBC Group, a Japanese global trading company.
“I’m proud of what we have done in these last 20 years, but everything was only possible thanks to our people,” said CEO Enrico Zodio, who has led Procos since 2010 and was named CEO of the Year at the Convention on Pharmaceutical Ingredients Pharma Awards in 2023.
To ensure its sustained growth, Procos laid out a 10-year plan anchored on a two-phase R11 project, a new facility that will boost its production capacity and strengthen its technological capabilities.
The first phase, which cost more than $70 million, is complete and will increase output by about 15%.
“We want to grow harmonically, organically and sustainably,” said Zodio, who believes the R11 project will lead to higher-value services. He added that new investments will also include the third expansion of the HPAPI (highly potent active pharmaceutical ingredients) Department, and a new research and development center.
Since the CBC acquisition, Procos has more than doubled its workforce to around 550 people.
Zodio credits CBC’s long-term commitment to life sciences for supporting capital-intensive projects that keep the Italian site globally competitive.